RQ Bio is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections.
Location: United Kingdom, England, London
Employees: 1-10
Investors 2
| Date | Name | Website |
| 23.12.2024 | Oxford Uni... | innovation... |
| - | Life Arc V... | lifearcven... |
Mentions in press and media 5
| Date | Title | Description |
| 18.03.2024 | RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19 | RQ Biotechnology Ltd. (“RQ”) a leader in the discovery of antibodies for the treatment of infectious disease, today announced that the UK Intellectual Property Office (IPO) has granted its patent application covering the company’s monoclona... |
| 25.01.2024 | Six new investments, portfolio progress and an expanding investment team | Clare Terlouw, Head of LifeArc Ventures, said: “Our portfolio of investments expanded during the year and despite challenging financing conditions in the sector we were pleased to invest in six new companies and to continue to support our e... |
| 10.01.2023 | LifeArc portfolio company RQ Bio’s antibody enters clinical trials | LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD3152, has entered clinical trials – less than 12 months after discovery... |
| - | AbCellera and RQ Bio Partner | VANCOUVER, British Columbia & LONDON, March 22, 2023 – AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease ... |
| - | LifeArc portfolio company RQ Bio’s antibody enters clinical trials | LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD3152, has entered clinical trials – less than 12 months after discovery... |